To view enhanced content for this article go to http://www.medengine.com/Redeem/03E6F06001883855.
The broth microdilution method (BMD) for testing telavancin minimum inhibitory concentrations (MICs) was revised (rBMD) in 2014 to improve the accuracy, precision, and reproducibility of the testing method. The aim of this study was to determine the effect of the revised method on telavancin MIC values for Staphylococcus aureus (S. aureus) clinical isolates obtained from hospital-acquired pneumonia (HAP) patients.
Isolates from patients who participated in the phase 3 Assessment of Telavancin for Treatment of HAP Studies were retested using the rBMD method.
Retesting of 647 isolates produced a range of telavancin MIC values from 0.015 µg/mL to 0.12 µg/mL with MIC50/90 values of 0.06/0.06 µg/mL for the total pool of samples. For methicillin-resistant S. aureus (MRSA), MIC50/90 values were 0.06/0.12 µg/mL. These values are up to 4-fold lower than MIC50/90 values obtained using the original method. These results were used in part to justify lowering the telavancin breakpoints. All tested isolates remained susceptible to telavancin at the revised susceptibility breakpoint of ≤0.12 µg/mL. Overall, the clinical cure rate for microbiologically evaluable telavancin-treated patients was 78% for S. aureus, 76% for patients with MRSA, and 79% for patients with isolates with reduced susceptibility to vancomycin (MIC ≥1 µg/mL).
Results from the rBMD method support the in vitro potency of telavancin against S. aureus.
ATTAIN (NCT00107952 and NCT00124020).
Theravance Biopharma Antibiotics, Inc.
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111. CrossRefPubMed
Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315–20. CrossRefPubMedPubMedCentral
Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49(3):1127–34. CrossRefPubMedPubMedCentral
VIBATIV ® (telavancin), USP [package insert]. South San Francisco: Theravance Biopharma US, Inc; 2016.
Summary of Product Characteristics (VIBATIV 250 mg powder for concentrate for solution for infusion) Bridgend, United Kingdom: Biotec Services International Limited; 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001240/WC500115364.pdf. Accessed Jan 4, 2016.
Theravance Biopharma Announces Marketing Authorization for VIBATIV(R) (Telavancin) in Russia for Treatment of Multiple Infections Caused by Gram-Positive Bacteria, Including MRSA Dublin, Ireland: Theravance Biopharma; 2015. http://investor.theravance.com/releasedetail.cfm?releaseid=920028. Accessed Jan 4, 2016.
CLSI. Performance standards for antimicrobial susceptibility testing; twenty-fourth international supplement. Wayne, PA: Clinical Laboratory and Standards Institute; 2014.
Mendes RE, Flamm RK, Farrell DJ, Sader HS, Jones RN. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. J Chemother; 2015:1973947815Y0000000050.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S. Clinical and Laboratory Standards Institute; 2016.
- Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
Jennifer I. Smart
Gordon Ralph Corey
Martin E. Stryjewski
Steven L. Barriere
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II